1. Home
  2. NRIX vs VET Comparison

NRIX vs VET Comparison

Compare NRIX & VET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$19.18

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Vermilion Energy Inc.

VET

Vermilion Energy Inc.

HOLD

Current Price

$8.61

Market Cap

1.4B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
VET
Founded
2009
1994
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
NRIX
VET
Price
$19.18
$8.61
Analyst Decision
Strong Buy
Analyst Count
13
0
Target Price
$26.77
N/A
AVG Volume (30 Days)
1.9M
1.4M
Earning Date
01-27-2026
11-05-2025
Dividend Yield
N/A
4.22%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$83,687,000.00
$1,445,514,003.00
Revenue This Year
$58.38
$9.23
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
48.32
30.48
52 Week Low
$8.18
$5.14
52 Week High
$22.50
$10.49

Technical Indicators

Market Signals
Indicator
NRIX
VET
Relative Strength Index (RSI) 66.53 47.89
Support Level $19.02 $8.54
Resistance Level $22.50 $9.28
Average True Range (ATR) 1.18 0.35
MACD 0.10 -0.07
Stochastic Oscillator 52.01 22.56

Price Performance

Historical Comparison
NRIX
VET

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About VET Vermilion Energy Inc.

Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.

Share on Social Networks: